Why LEADS Matters

Alzheimer’s disease is a national crisis, with more than 5 million Americans living with the disease and 16 million friends and family serving as caregivers. In addition, as many as 300,000 individuals with Alzheimer’s are under age 65, meaning they have the early-onset form of the disease.

The Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s.
To move toward more effective treatments, scientists need to understand the genetic, biological and clinical processes involved in early-onset Alzheimer’s disease. Your participation in LEADS could contribute to future medical advances to help all those affected by Alzheimer’s disease.